Kavanaugh 2011.

Methods	This was a randomised, placebo‐controlled trial (GO‐REVEAL study).
Participants	Inclusion criteria of the trial Psoriatic arthritis participants with 3 swollen and 3 tender joints and psoriasis. The trial lasted for 104 weeks, and it included 405 participants.
Interventions	Subcutaneous placebo (group 1) Golimumab 50 mg (group 2) Golimumab 100 mg (group 3) The interventions were administered every 4 weeks. At week 16, participants with inadequate response entered early escape. Group 1 crossed over to golimumab 50 mg at week 24. In open‐label extension, participants could be dose‐escalated, from golimumab 50 mg to 100 mg.
Outcomes	Outcomes of the trial Improvement of target fingernail psoriasis Adverse effects
Notes	This was a conference publication.